 PLANO, Texas--BUSINESS WIRE--Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata, the Company, our, us, or we, a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on the Companys business operations and clinical development programs pre-market on February 28, 2022. Conference Call Information Reatas management will host a conference call on February 28, 2022, at 8:30 a.m. ET. The conference call will be accessible 